Improved amino acid, bioenergetic metabolite and neurotransmitter profiles following human amnion epithelial cell transplant in intermediate maple syrup urine disease mice

Molecular Genetics and Metabolism

Volumn 109, Issue 2, 2013, Pages 132-138

  Skvorak, Kristen J ^a   Dorko, Kenneth ^a   Marongiu, Fabio ^e   Tahan, Veysel ^a   Hansel, Marc C ^a   Gramignoli, Roberto ^b   Arning, Erland ^c   Bottiglieri, Teodoro ^c   Gibson, K Michael ^d   Strom, Stephen C ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Amnion; Epithelium; Liver; Metabolic; Transplant

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; BRANCHED CHAIN AMINO ACID; DOPAMINE; HOMOVANILLIC ACID; NEUROTRANSMITTER; SEROTONIN;

AMINO ACID BLOOD LEVEL; AMINO ACID BRAIN LEVEL; AMNION CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENERGY; BODY WEIGHT; CARCINOGENICITY; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EPITHELIUM CELL; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LIFESPAN; LIVER CELL; MAPLE SYRUP URINE DISEASE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SURVIVAL; UREA CYCLE;

AMINO ACIDS; AMNION; ANIMALS; BRAIN; CITRIC ACID CYCLE; EPITHELIAL CELLS; HUMANS; MAPLE SYRUP URINE DISEASE; MICE; MICE, TRANSGENIC; NEUROTRANSMITTER AGENTS;

ACER; MURINAE; MUS;

EID: 84878489730     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.02.011     Document Type: Article

References (39)

1. Chuang D.T., Shih V.E. The Metabolic and Molecular Bases of Inherited Disease 2001, vol. 2:1971-2005. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Snyderman S.E., Norton P.M., Roitman E., L.E.H. Maple syrup urine disease, with particular reference to dietotherapy. Pediatrics 1964, 34:454.
3. Strauss K.A., et al. Elective liver transplantation for the treatment of classical maple syrup urine disease. Am. J. Transplant. 2006, 6:557.
4. Skvorak K., et al. Liver Transplantation - Technical Issues and Complications 2012, InTech. H. Abdeldayem, N.A.A. Allam (Eds.).
5. Jorns C., et al. Hepatocyte transplantation for inherited metabolic diseases of the liver. J. Intern. Med. Sep 2012, 272:201.
6. Skvorak K.J., et al. Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD). Biochim. Biophys. Acta 2009, 1792:1004.
7. Skvorak K.J., et al. Hepatocyte transplantation improves phenotype and extends survival in a murine model of intermediate maple syrup urine disease. Mol. Ther. Jul 2009, 17:1266.
8. Hamman K., Clark H., Montini E., et al. Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. Mol. Ther. 2005, 12:337.
9. Strom S.C., et al. Hepatocyte transplantation: clinical experience and potential for future use. Cell Transplant. 2006, 15(Suppl. 1):S105.
10. Fisher R.A., Strom S.C. Human hepatocyte transplantation: worldwide results. Transplantation 2006, 82:441.
11. Horslen S.P., et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003, 111:1262.
12. Fox I.J., et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N. Engl. J. Med. 1998, 338:1422.
13. Dhawan A., Puppi J., Hughes R.D., Mitry R.R. Human hepatocyte transplantation: current experience and future challenges. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:288.
14. Waelzlein J.H., Puppi J., Dhawan A. Hepatocyte transplantation for correction of inborn errors of metabolism. Curr. Opin. Nephrol. Hypertens. 2009, 18:481.
15. Lysy P.A., et al. Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives. World J. Gastroenterol. 2008, 14:3464.
16. Miki T., Marongiu F., Dorko K., Ellis E.C., Strom S.C. Isolation of amniotic epithelial stem cells. Curr. Protoc. Stem Cell Biol. Jan 2010, 3. (Chapter 1, Unit 1E).
17. Mamede A.C., et al. Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res. May 18 2012, 349(2):447-458.
18. Li H., Niederkorn J.Y., Neelam S., et al. Immunosuppressive factors secreted by human amniotic epithelial cells. Invest. Ophthalmol. Vis. Sci. 2005, 46:900.
19. Miki T., Lehmann T., Cai H., Stolz D.B., Strom S.C. Stem cell characteristics of amniotic epithelial cells. Stem Cells Nov-Dec 2005, 23:1549.
20. Akle C.A., Adinolfi M., Welsh K.I., et al. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet 1981, 2:1003.
21. Miki T., Strom S.C. Amnion-derived pluripotent/multipotent stem cells. Stem Cell Rev. 2006, 2:133.
22. Davis J.W. Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital. Johns Hopkins Med. J. 1910, 15:307.
23. Dua H.S., Gomes J.A., King A.J., Maharajan V.S. The amniotic membrane in ophthalmology. Surv. Ophthalmol. 2004, 49:51.
24. Akle C., et al. Transplantation of amniotic epithelial membranes in patients with mucopolysaccharidoses. Exp. Clin. Immunogenet. 1985, 2:43.
25. Cerneca F., et al. Treatment of patients with Niemann-Pick type is using repeated amniotic epithelial cells implantation: correction of aggregation and coagulation abnormalities. Clin. Pediatr. (Phila) 1997, 36(141).
26. Yeager A.M., et al. A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases. Am. J. Med. Genet. Oct 1985, 22:347.
27. Marongiu F., et al. Hepatic differentiation of amnion epithelial cells. Hepatology 2011, 53:1719.
28. Miki T., et al. Production of hepatocyte-like cells from human amnion. Methods Mol. Biol. 2009, 481:155.
29. Skvorak K.J., et al. Placental stem cell corrections of murine intermediate maple syrup urine disease. Hepatology 2012, 57(3):1017-1023.
30. Zinnanti W.J., et al. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Brain Apr 2009, 132:903.
31. Yudkoff M. Brain metabolism of branched-chain amino acids. Glia 1997, 21:92.
32. Yudkoff M., et al. Brain amino acid requirements and toxicity: the example of leucine. J. Nutr. Jun, 2005, 135:1531S.
33. McKenna M.C., et al. Alpha-ketoisocaproate alters the production of both lactate and aspartate from [U-13C]glutamate in astrocytes: a 13C NMR study. J. Neurochem. Mar 1998, 70:1001.
34. Tribble D., Shapira R. Myelin proteins: degradation in rat brain initiated by metabolites causative of maple syrup urine disease. Biochem. Biophys. Res. Commun. Jul 29 1983, 114:440.
35. Schonberger S., Schweiger B., Schwahn B., Schwarz M., Wendel U. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol. Genet. Metab. May 2004, 82:69.
36. Skvorak K.J. Animal models of maple syrup urine disease. J. Inherit. Metab. Dis. Apr, 2009, 32:229.
37. JAX Genotyping Protocols Database 2009, JAX, Bar Harbor.
38. Slocum R.H., Cummings J.G. Techniques in Diagnostic Human Biochemical Genetics 1991, 87-126. Wiley-Liss, New York. F.A. Hommes (Ed.).
39. Ogburn K.D., Bottiglieri T., Wang Z., Figueiredo-Pereira M.E. Prostaglandin J2 reduces catechol-O-methyltransferase activity and enhances dopamine toxicity in neuronal cells. Neurobiol. Dis. 2006, 22:294.